Show notes

Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study

https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study



Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars

https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars



IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years

https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years



Vizient Report Predicts Over 3% Inflation Rate for Biologics

https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics



On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars

https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars



Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations

https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations



Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars

https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars